Profiel
Chengwen Li is the founder of GeneVentiv Therapeutics, Inc. He currently holds a position as Director at Nabgen, Inc.
Actieve functies van Chengwen Li
| Bedrijven | Functie | Begin |
|---|---|---|
GeneVentiv Therapeutics, Inc.
 GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Oprichter | - |
| Nabgen, Inc. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
GeneVentiv Therapeutics, Inc.
GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Health Technology |
| Nabgen, Inc. |
